Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
NCT06326476
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Hidradenitis Suppurativa
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Early Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Alabama at Birmingham
- Last updated on ClinicalTrials.gov
- September 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.